Anavex Life Sciences Stock Price

-0.26 (-1.94%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Anavex Life Sciences Corporation AVXL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.26 -1.94% 13.17 09:48:38
Open Price Low Price High Price Close Price Prev Close
13.29 13.1489 13.53 13.43
Bid Price Ask Price Spread News
13.17 13.25 0.08 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
624 107,888 $ 13.26 $ 1,430,567 1,329,756 3.01 - 28.6499
Last Trade Time Type Quantity Stock Price Currency
09:49:17 7 $ 13.1701 USD

Anavex Life Sciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 890.61M 66.96M 64.62M $ - $ - -0.45 -13.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Anavex Life Sciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AVXL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week15.0115.7413.0614.16987,560-1.84-12.26%
1 Month15.6016.1612.800114.741,503,510-2.43-15.58%
3 Months6.0428.64995.5613.744,314,1237.13118.05%
6 Months4.4528.64994.3011.392,772,8358.72195.96%
1 Year3.1228.64993.019.941,704,71510.05322.12%
3 Years2.1728.64991.257.37924,96611.00506.91%
5 Years5.6628.64991.256.43814,9057.51132.69%

Anavex Life Sciences Description

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company operating in the United States. It is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer's disease, other central nervous systems (CNS) diseases, pain and several types of cancer. The lead compound of the company is ANAVEX 2-73 which is developed to treat Alzheimer's disease, Parkinson's disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome. The research and development pipeline of the company includes one clinical drug candidate and several compounds in various stages of the pre-clinical study.

Your Recent History
Anavex Lif..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.